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SUMMARY 
The purpose of this study was to species-identify clinical isolates of genus Bacteroides 
previously submitted to the National Veterinary Institute (SVA) and to determine their 
antimicrobial susceptibility to penicillin and other antimicrobials commonly used in horses in 
Sweden. The 29 isolates included in the study were identified as Bacteroides fragilis (n=10), 
Bacteroides heparinolyticus (n=7), Bacteroides ovatus (n=2), Bacteroides thetaiotaomicron 
(n=2), Bacteroides pyogenes (n=1), Parabacteroides distasonis (n=2), Prevotella sp. (n=2), 
Prevotella dentasini (n=1), Porphyromonas sp. (n=1) and Fusobacterium sp. (n=1). 
Identification of Bacteroides spp. using matrix-assisted-laser-desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) has proved to be a time and cost effective 
method for species-identification of bacteria. Bacteroides fragilis, B. ovatus, B. 
thetaiotaomicron and P. distasonis all showed resistance against penicillin. The only 
Bacteroides spp. showing susceptibility to penicillin was B. heparinolyticus and B. pyogenes. 
Bacteroides fragilis showed resistance to many other antimicrobials used in horses such as 
ampicillin, gentamicin, ceftiofur erythromycin and trimethoprim/sulphamethoxazole. Few 
antimicrobials available for treatment of horses in Sweden proved effective against B. fragilis. 
Unfortunately it was not possible to test the isolates for susceptibility towards metronidazole; 
however, internationally, metronidazole resistance is extremely rare even in human isolates, 
and it would not be expected to find resistant isolates from horses in Sweden. 
 
 
 
  
SAMMANFATTNING 
Syftet med denna studie var att artidentifiera kliniska isolat av genus Bacteroides som tidigare 
har skickats till Statens Veterinärmedicinska Anstalt (SVA) och testa deras känslighet för 
antibiotika som används till häst i Sverige som till exempel penicillin. De 29 isolaten som 
inkluderades i denna studie identifierades som Bacteroides fragilis (n=10), Bacteroides 
heparinolyticus (n=7), Bacteroides ovatus (n=2), Bacteroides thetaiotaomicron (n=2), 
Bacteroides pyogenes (n=1), Parabacteroides distasonis (n=2), Prevotella sp. (n=2), 
Prevotella dentasini (n=1), Porphyromonas sp. (n=1) och Fusobacterium sp. (n=1). 
Identifiering med matrix-assisted-laser-desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) visade sig vara en snabb och säker metod för artidentifiering av bakterier. 
Bacteroides fragilis, B. ovatus, B.thetaiotaomicron och P. distasonis var alla resistenta mot 
penicillin. Endast B. heparinolyticus och B. pyogenes var känsliga för penicillin av alla 
Bacteroides-arter. Bacteroides fragilis uppvisade resistens mot många andra antibiotika som 
ingick i studien. Bacteroides fragilis var resistant mot ampicillin, gentamicin, ceftiofur, 
erythromycin och trimetoprim/sulfametoxazol. Få antibiotika tillgängliga på den svenska 
marknaden var effektiva mot B. fragilis. Tyvärr var det ej möjligt att testa isolaten för 
känslighet mot metronidazol. Internationell litteratur rapporterar dock en väldigt låg frekvens 
av metronidazol-resistens för isolat från djur och människor, och det är osannolikt att isolat av 
Bacteroides spp. från häst i Sverige är resistenta. 
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INTRODUCTION 
Bacteria of the genus Bacteroides are important pathogens involved in many different 
infections in horses. It is critical that these horses are treated with appropriate antimicrobial 
therapy. The current guidelines for the use of antimicrobials in horses in Sweden recommend 
the use of penicillin as a primary antimicrobial in most infectious processes. However, it is 
not clear to which extent penicillin-resistant Bacteroides spp. exist in Sweden. In the literature 
it is possible to identify Bacteroides fragilis as highly resistant to penicillin, whilst other 
members of the genus would appear to be more susceptible to penicillin. In human literature it 
is possible to identify an increasing trend in resistance to antimicrobials within the genus 
Bacteroides. Therefore it is important to know which species of Bacteroides that is involved 
in the infection to determine the most appropriate antimicrobial agent.  
Unfortunately antimicrobial susceptibility results for clinical samples of Bacteroides spp. sent 
to the National Veterinary Institute are not available, as the testing is not performed. Because 
of this, it is possible that horses are treated with antimicrobials with little or no effect against 
these pathogens. Currently the laboratory only identifies the clinical isolates of Bacteroides 
spp. to genus level, and species level identification is unavailable for these samples. However, 
with new emerging techniques for identification of isolated organisms it would be possible to 
species- identify these pathogens. The purpose of this study was to determine the 
antimicrobial susceptibility of clinical isolates of previously identified Bacteroides spp. and to 
species identify these isolates using matrix-assisted-laser-desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) or 16S rRNA gene sequencing. This is important as it 
needs to be determined to which extent penicillin-resistant Bacteroides spp. exist in clinical 
isolates from horses. This was done in order to gain more understanding of the Bacteroides 
spp. involved in equine infections and to suggest treatment regimens for these infections. 
LITTERATURE REVIEW 
Genus Bacteroides 
Bacteria of the genus Bacteroides are anaerobic, Gram-negative and non-spore forming rods. 
The Bacteroides genus has undergone several recent taxonomic changes and organisms 
formerly known as Bacteroides have now been moved into several other genera including 
Parabacteroides, Prevotella, Porphyromonas and Tannerella. (Jousimies-Somer et al.,2003; 
Sakamoto & Benno, 2006; Sakamoto et al., 2002, Shah & Collins, 1988; 1989; 1990; Wexler, 
2007). This might cause confusion but is important to both clinicians and microbiologists as 
the taxonomic placement can be an indicator of potential virulence and antimicrobial 
resistance (Wexler, 2007). 
Much research has been done on Bacteroides spp. in humans, but by comparison little has 
been done in animals and clinical cases involving Bacteroides spp. They are however an 
important part of infections in animals and according to a recent study make up about 8% of 
anaerobic infections in horses, 11% in dogs and 24% in cats (Lawhon et al., 2013). Earlier 
reports state that Bacteroides spp. make up 24% of anaerobic infections in dogs and 22% in 
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cats (Jang et al., 1997). An older study establishes that Bacteroides spp. make up about 44% 
of all anaerobic isolates (Hirsh et al., 1985, Jang et al., 1991) which reflects the results of an 
even older study that found Bacteroides spp. in 46% of clinical anaerobic isolates from 
animals (Hirsh et al., 1979). However, it is important to note that since then the species 
included in the Bacteroides genus has changed dramatically which might explain why the 
more recent data suggest a lower percentage involvement of Bacteroides spp. It is also 
important to note that when looking at more specific categories of disease involving 
Bacteroides spp. the percentage of infections involving the genus is higher. For example, in 
lower respiratory tract infections in horses research shows that 26% of all samples cultured 
are positive for anaerobic growth (Hirsh et al., 1985). 
Bacteroides spp. are part of the normal flora of the gastrointestinal tract in both humans and 
animals and they are also part of the normal flora of the mouth, urogenital tract and the upper 
respiratory tract in humans (Jousimies-Somer et al., 2003). Fecal isolates from the gut flora in 
humans is comprised of about 30% of bacteria belonging to the genus Bacteroides (Salyers, 
1984) and the genus is the most commonly isolated of the anaerobic bacteria in clinical 
samples with Bacteroides fragilis being the most commonly isolated pathogen (Jousimies-
Somer et al.,2003; Nagy et al., 2010; Polk & Kasper, 1977). One study looking at the bovine 
intestinal flora found that 17% was Bacteroides spp. (Wagner et al., 2011). Bacteroides 
fragilis is considered the most virulent of the Bacteroides spp. as the number of isolates of B. 
fragilis is 10 to 100-fold less than other Bacteroides spp. isolates in the gut, yet in humans it 
is the most frequently isolated from clinical specimens (Wexler, 2007). In animals B. fragilis 
used to be isolated very infrequently (Kimsey & Hirsh 1978, Hirsh et al., 1979). However, 
with better methods for culturing of anaerobic bacteria there has been an increase in the 
isolation of B. fragilis from animals (Hirsh et al., 1985).  
Virulence 
The genus Bacteroides is important because the bacteria have several mechanisms which 
make them well suited to turn from a commensal to a pathogen. Bacteroides fragilis in 
particular have fimbriae and agglutinins that function as adhesins, which allow them to 
become established in host tissues where you will normally not find Bacteroides (Wexler, 
2007). They possess various enzymes that protect the bacteria from the host’s immune system 
and immune response and it has been shown that after interaction with B. fragilis 
macrophages will show decreased nitric oxide (NO) production. Macrophages produce NO as 
an important early immune response which normally has a microbiocidal effect on bacteria 
(Vieira et al., 2005). This allows B. fragilis to effectively evade the host’s immune system. 
Bacteroides fragilis also possess a capsule with structural polysaccharides which makes it 
highly capable of inducing abscess formation as a lone infecting organism (Tzianabos et al., 
1993). Bacteroides fragilis also produce enzymes which can cause tissue destruction. These 
are histolytic enzymes, some of which attack the host’s extracellular matrix (Rudek & Haque 
1976). Some of the proteases produced by B. fragilis have been implicated in destroying the 
brush border enzymes required for digestion of food and required for selective absorption of 
nutrients. It has also been shown that B. fragilis produce an enterotoxin which may cause 
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diarrhea by destroying tight junctions in intestinal epithelium (Wu et al., 1998, Almeida et al., 
2007). These potent virulence factors contribute to B. fragilis being the most commonly 
isolated of the anaerobic pathogens (Polk & Kasper, 1977). 
To illustrate the virulence of B. fragilis it has been noted in humans that the mortality of 
infections involving B. fragilis is more than 19%, and if an infection with B. fragilis is left 
untreated the mortality rate is about 60% (Goldstein, 1996). 
Antimicrobial susceptibility 
Internationally there are few recent reports on antimicrobial susceptibility in Bacteroides spp. 
in animals and most treatment decisions are based on older studies. The few recent reports 
would suggest however, that Bacteroides show resistance to many antimicrobials used in 
horses, cattle, dogs and cats (Lawhon et al., 2013, Wagner et al., 2011, Almeida et al., 2007) 
and studies conducted in humans echo the same results (Nagy et al., 2010; Ulger-Toprak et 
al., 2004). Resistance to penicillin, ampicillin, amoxicillin, ceftiofur and cefoxitin is not 
uncommon.  
Frequently, susceptibility patterns of anaerobes isolated from humans are used in veterinary 
practice since limited data is available for animals. However, this might not be optimal as 
susceptibility patterns of anaerobes in animals might be different to those in humans as the 
antimicrobial use differs between the two groups. Both the frequency of which an 
antimicrobial is used and which antimicrobials are used differs between countries and species. 
Care needs to be taken interpreting susceptibility data for Bacteroides spp., as the species are 
usually grouped into their genus when results are published. However, the antimicrobial 
susceptibility varies within the group and data displayed in this fashion can be misleading to 
clinicians and can cause confusion when making decisions of antimicrobial therapy. Also, 
general statements are commonly made that the anaerobes are susceptible to penicillin. This is 
true for many other anaerobes which generally are susceptible, but is not suitable when 
discussing Bacteroides spp.  
Studies on isolates from human patients demonstrate a high resistance to different 
antimicrobials in Bacteroides spp. and treatment needs to be selected based on the outcome of 
susceptibility tests. The medical community is seeing a rapid rise in resistance to many 
antimicrobials to which Bacteroides spp. were previously sensitive such as ampicillin, 
amoxicillin/clavulanic acid, cefoxitin and clindamycin (Nagy et al., 2010). Resistance to 
penicillin is almost universal in Bacteroides spp. isolated from humans (Franklin et al., 2006; 
Aldridge et al., 2001; Nagy et al., 2010; Ulger-Toprak et al., 2004). Isolates of Bacteroides 
spp. from different animal species show similar resistance to antimicrobials as those from 
humans, but the frequency at which resistant strains are encountered is lower (Franklin et al., 
2006). It is of importance to note that many strains of Bacteroides spp. produce β-lactamases 
and would therefore make them highly unsuitable candidates for treatment with penicillin, 
ampicillin and most of the cephalosporins (Ulger-Toprak et al., 2004; Jousimies-Somer et al., 
2003). High resistance has been noted to these substances in both human and animal 
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literature. One study found β-lactamase production in up to 99% of tested isolates from 
humans (Ulger-Toprak et al., 2004). It has been noted by Hirsh et al. even as early as 1985 
that members of the Bacteroides genus isolated from animals show high resistance to 
penicillin, ampicillin and cephalothin. Bacteroides fragilis made up 68% of the resistant 
isolates in that study. The same study also noted that one third of penicillin-resistant 
Bacteroides also showed resistance to tetracycline. It is also known that members of the genus 
Bacteroides can be resistant to β-lactam antimicrobials even without β-lactamase production. 
These strains have alternate means of resistance such as alteration of their penicillin binding 
proteins (PBPs) or by having an altered permeability to β-lactams (Fang et al., 2002; Hedberg 
et al,. 1997). One study looking at bovine intestinal bacteria has shown that the antimicrobials 
ceftiofur and ceftriaxone are degraded in the intestine by several different bacteria, and that up 
to 96% of intestinal organisms inactivate ceftiofur to some extent (Wagner et al., 2011). The 
same study showed that Bacteroides spp. as a group was the second most efficient at ceftiofur 
degradation.  
Bacteroides spp. are still showing very low frequency of resistance to antimicrobials such as 
imipenem, metronidazole, chloramphenicol and tigecycline (Nagy et al., 2010; Almeida et al., 
2007; Aldridge et al., 1994). Resistance to piperacillin/tazobactam is still low, but would 
appear to be increasing (Aldridge et al., 2001; Nagy et al., 2010). 
Susceptibility testing of Bacteroides spp. is not routinely performed at the National 
Veterinary Institute (SVA), which leaves out a vital piece of information for the clinician. 
Isolates recognized as Bacteroides spp. are not identified further to species-level since there 
have not been methods readily available to perform this. Knowledge about antimicrobial 
susceptibility is important in the decision-making in determining the most appropriate 
antimicrobial treatment in clinical cases. This is true for any bacterial infection, but very 
important in infections with bacteria that are known to be resistant to many antimicrobials. In 
the clinical setting, choice of antimicrobial treatment is decided before results of culture and 
susceptibility is known. Knowledge of the susceptibilities of the most common microbes is 
therefore central to a correct choice of antimicrobial before the final result of the 
susceptibility test. For example it has been noted that Bacteroides thetaiotaomicron displays 
resistance to more antimicrobials than B. fragilis (Wexler 2007; Ulger-Toprak et al., 2004).  
When considering which antimicrobial to use for a patient, the veterinarian not only needs to 
consider which would be the most appropriate for the isolated organism, but also if it is 
possible to reach the levels required for the antimicrobial to have its effect. The veterinarian 
also needs to consider if the antimicrobial to be used is time-dependent or concentration-
dependent to ensure correct dosage regimens. For antimicrobials that are concentration-
dependent the aim would be to achieve a  high plasma concentration relative to the minimum 
inhibitory concentration (MIC) whereas if the antimicrobial is time-dependent the objective is 
to keep the concentration above MIC for the duration of the dosage intervals (Giguère 2013). 
There are a few drugs which are both time and concentration-dependent, but they are used in 
extremely rare cases of horses in Sweden. 
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When deciding which antimicrobial to use it is also important to consider the clinical MIC 
breakpoint of the antimicrobial against a specific organism in the target location in the horse. 
Many clinical breakpoints are derived from human literature and for other organs or tissues in 
the body. These breakpoints might not be transferrable to horses or to the target site of 
infection. Clinical breakpoints are relevant only for the specific drug in a specific organ 
system against a specific bacterium (Giguère & Afonso, 2013). However, not all of this 
information is available in the horse as less research has been done in horses, and often 
veterinary clinicians have to use clinical breakpoints set in humans when evaluating which 
antimicrobial to use. Often used clinical breakpoints are those from the Clinical and 
Laboratory Standards Institute (CLSI) and EUCAST (European Committee on Antimicrobial 
Susceptibility Testing). 
In Sweden frequently used antimicrobials in horses include penicillin, gentamicin, and 
trimethoprim-sulfonamide combination. Other antimicrobials used in horses include 
tetracycline, ceftiofur and metronidazole. Rifampicin is used in foals with Rhodococcus equi 
infections. Penicillin, tetracycline, trimethoprim-sulfonamide, and ceftiofur are all time-
dependent and frequent administrations are required to keep the concentration above MIC 
(Giguère, 2013). Gentamicin and metronidazole are concentration-dependent, and it is not 
necessary to keep the concentration of the drug above MIC between doses (Giguère, 2013). 
Many other antimicrobials are not readily available for use in horses and many are restricted 
by law for use in animals as they are reserved for severe cases of disease in humans (Statens 
Jordbruksverks Författningssamling, SJVFS 2012:32). Some antimicrobials that exist in an 
appropriate solution abroad do not exist in Sweden such as chloramphenicol which is only 
available in ophthalmic solutions.  
It has been suggested that a combination of penicillin against Gram-positive and anaerobic 
bacteria together with gentamicin against Gram-negative bacteria give good coverage in 
severe bacterial infections in horses until results of culture and susceptibility testing is 
received (Giguère & Afonso, 2013). 
Bacteroides spp. in horses 
To the author’s knowledge, there are no studies on antimicrobial susceptibility of Bacteroides 
spp. isolated from horses in Sweden. The current consensus in Sweden is to treat horses with 
infections involving Bacteroides spp. with penicillin as a first choice antimicrobial (Sveriges 
Veterinärmedicinska Sällskap, 2013) as it is not clear to which extent penicillin resistant B. 
fragilis occur in Sweden. 
Since Bacteroides spp. are part of the normal anaerobic flora in the horse and because of its 
easy transition from commensal to pathogen it is not surprising that it is isolated from clinical 
cases in horses. However, the true frequency of infections involving Bacteroides spp. might 
be higher as frequently no anaerobic culture will be requested as it means added costs for the 
client. It also demands that the clinician knows the proper technique for anaerobic sampling 
of the affected area. There are few international studies done on Bacteroides spp. and 
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antimicrobial susceptibility exclusively from horses, and case reports are few and far between. 
Examples of infections involving Bacteroides spp. in horses are paraoral and lower 
respiratory tract infections (Bailey & Love, 1991; Sweeney et al., 1985; 1991a; Mair & Lane, 
1989), endometritis (Hariharan, 1994), abscesses (Spiers et al.,1986; Jang & Hirsh, 1991), 
peritonitis (Sweeney et al., 1991b; Mair et al., 1990) diarrhea in foals (Myers et al., 1987) and 
wounds (Lawhon et al., 2013; Jang & Hirsh, 1991). But there are also examples of more 
uncommon occurrences of infections with Bacteroides spp. such as keratitis (Johns, 2009). 
Infections involving the respiratory tract 
It has been shown in horses that bacteria involved in lower respiratory tract (LRT) infections 
and paraoral infections most likely come from the bacterial flora from the oral cavity (Bailey 
& Love, 1991). The same species were isolated from the normal pharyngeal tonsillar surfaces 
and from LRT and paraoral infections. It was shown that Bacteroides spp. comprised about 
50% of the isolates from normal pharyngeal tonsillar surface samples and about 21% of 
anaerobic isolates from LRT and paraoral infections, with LRT infections having a slightly 
higher percentage at 30%.  
These results are similar to what Sweeney et al. (1991a) reported which is that out of all the 
anaerobic bacteria isolated, Bacteroides spp. made up 20.2% of anaerobes found in clinical 
cases of pneumonia and pleuropneumonia. The same study also reported that strictly 
anaerobic infections made up about 2.0% of pleuropneumonia or pneumonia cases. But 
anaerobes in mixed infections with aerobes represent about 24.8% of cases. In a review of 45 
cases of pneumonia and lung abscesses, 6 of 11 cases of primary pneumonia and lung abscess 
cases were tested for anaerobes. Three of the six (50%) samples resulted in anaerobic isolates 
and they all contained at least one Bacteroides sp. (Mair & Lane 1989)  
There was also a poorer prognosis for horses with anaerobic or mixed infections with survival 
rates of 38.3% versus horses with only aerobic isolates with a survival rate of 81.4% 
(Sweeney et al., 1991a). In an earlier study from Sweeney et al. (1985) it was found that in 
46% of horses with pleuropneumonia anaerobic bacteria were isolated, and Bacteroides oralis 
and Bacteroides melaninogenicus (now classified as Prevotella oralis and Prevotella 
melaninogenica) were the anaerobes most frequently isolated. The two studies show a similar 
survival rate for horses with an involvement of anaerobic bacteria in pleuropneumonia to be 
33.3% (Sweeney et al., 1985) and 38.3% (Sweeney et al., 1991a) which indicates that 
infection with anaerobic bacteria is a serious condition and rapid correct therapy is vital. 
Bacteroides spp. in wounds and abscesses 
The anaerobic microbiology of equine wounds is poorly researched, and few reports 
describing the types of bacteria inhabiting equine wounds exist. However, using information 
from other species it is clear that anaerobes are involved and is a relevant component of these 
infectious processes. A recent study on resistance in obligate anaerobes from animals reports 
the presence of Bacteroides spp. in subcutaneous tissue and wounds in horses (Lawhon et al., 
2013). A study by Jang & Hirsh (1991) reported frequent isolation of Bacteroides spp. from 
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abscesses and wounds in horses. However, a recent study looking solely at the microbiology 
of equine wounds found no involvement of Bacteroides spp. (Westgate et al., 2011). This is 
interesting as in humans it has been recorded that 7% of anaerobes in soft-tissue infections 
belong to the genus Bacteroides (Wexler et al.,, 1998), and another study concludes that 
Bacteroides was the most common organism isolated from mixed aerobic and anaerobic 
infections (Elliot et al., 2000). It is also interesting to note that Bacteroides spp. is very 
frequently involved in abscesses from fight-wounds in cats. One study found involvement of 
Bacteroides spp. in 44.5% of subcutaneous abscesses (Love et al., 1989). Love et al. (1989) 
draws the conclusion that the species involved in subcutaneous fight-wound abscesses in cats 
originate from the flora of the mouth. Interestingly, they noted a virtual absence of B. fragilis 
in these abscesses. The most commonly isolated species in this study was B. tectum, B. 
salivosus, B. gingivalis and B. heparinolyticus. 
Anaerobic infections should always be considered when aerobic cultures are negative. This is 
especially true for cases of osteomyelitis, drainage tracts and abscess formation. But both 
anaerobic and aerobic cultures should always be submitted (Spurlock & Hanie, 1989) 
Bacteroides spp. in cases of peritonitis 
Obligate anaerobic bacteria are isolated frequently from peritoneal cavities. Bacteroides spp. 
is the anaerobic genus isolated most often and it has been noted that B. fragilis can be 
involved in approximately 10-20% of positive cases (Hirsh & Jang 1987). In dogs and cats it 
has been noted that anaerobes are involved in 31% and 40% of cases of peritonitis 
respectively (Jang et al., 1997). The most commonly isolated species in this study included 
Bacteroides spp.  
Because many different species are involved in cases of peritonitis in the horse, it is crucial 
that correct culturing and susceptibility testing is performed to ensure correct antimicrobial 
therapy. Treatment in cases with peritonitis poses as problem as the infection is in the 
transcellular space and it can be difficult to get the concentration of antimicrobials high 
enough. However, Sweeney et al. (1986) showed that it is possible to achieve even higher 
levels of metronidazole in the peritoneal fluid than in serum, making it an ideal antimicrobial 
to treat horses with peritonitis involving anaerobic organism such as Bacteroides spp.  
In humans, the most common infection caused by Bacteroides spp. is intra-abdominal sepsis. 
A disruption of the intestinal wall caused by surgery or other malignancies such as traumatic 
injury or appendicitis, cause the flora of the gut to invade the sterile environment of the 
peritoneal cavity. Bacteroides spp. predominates in the second more chronic stage of 
infection, when sufficient oxygen has been removed (Wexler, 2007). Another study which 
looks at the microbiology of the peritoneal cavity in children after a perforated appendix 
found that Bacteroides spp. was recovered in 93% of cases (Brook, 2003). 
MALDI TOF MS 
Identifying Bacteroides spp. from a clinical sample takes time as it needs to grow at least 48 
hours before any kind of identification can be made. Most likely, another 48 hours is required 
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for identification of samples that are not in pure culture. After that, more work is needed for 
phenotypic identification. This is time consuming and high in cost. A new and quickly 
emerging way of identification of bacteria is by using matrix-assisted-laser-
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). With this method 
minimum sample preparation is necessary. Material from a single colony is taken and spotted 
onto a ground-steel MALDI target plate which is then introduced into the MALDI-TOF MS. 
Results take less than 1 minute to process per spot on the plate. This can be done from the 
primary culture and several colonies with different characteristics can be run simultaneously 
(Wieser et al., 2012). In human medicine, it is now possible to get results from blood-cultures 
within hours after the blood culture bottle is positive for growth through acquiring material by 
centrifuging liquid from the bottle, extract and purify the bacterial proteins and using this 
sample to spot onto the MALDI plate (Reviewed by Wieser et al., 2012). 
MALDI-TOF MS works by exposing each fixed sample to multiple pulsing laser beams that 
ionizes part of the sample. The ions travel to a detector through a flight tube. At the detector, 
differences in mass-to-ionic charge ratios cause the ions to separate. The results are collected 
electronically in spectral channels and converted into a mass value that is displayed as a 
spectrum. This spectrum is then compared to a library of spectrums in a software program 
(Reviewed by Wieser et al., 2012). 
MATERIALS AND METHODS 
Bacterial isolates 
A total of 31 bacterial isolates from clinical submissions between the years 2006-2013 were 
used in this study. The isolates were determined to be of genus Bacteroides by different 
phenotypical methods and frozen at the National Veterinary Institute (SVA) in Uppsala, 
Sweden at the time of submission. However the isolates were not species-identified as no 
method for this was available at the laboratory. All isolates were from equine patients from 
different clinics and hospitals around Sweden. The sources of the samples were wounds 
(n=7), peritoneal fluid (n=3), abscesses (n=7), aspirates from lungs and sinuses (n=7), fecal 
samples (n=2), one uterine sample (n=1), blood (n=1), synovial fluid (n=2) and unknown 
sample sites (n=1). The type strain B. fragilis ATCC 25285 was included as a control due to 
its known susceptibility pattern. 
Culturing and identification 
The isolates were cultured on fastidious anaerobe agar (FAA) supplemented with 10% horse 
blood (SVA, Uppsala, Sweden). The samples were incubated for 48 h in 37°C in a 2.5 liter 
anaerobic jar. The anaerobic environment was created using Oxoid AnaeroGen sachets 
(Oxoid Ltd, Basingstoke, UK). The samples were then recultured twice on FAA and 
incubated in 37°C for 48 h to ensure vitality of the bacteria.  
All isolates were analyzed by MALDI –TOF MS (Bruker Daltonik GmbH, Bremen, 
Germany) to identify the species. Mass spectra were compared against the 4613 spectra in the 
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MALDI Biotyper database using the MALDI Biotyper 3.0 Realtime Classification (RTC) 
software (Bruker Daltonik GmbH, Bremen, Germany).  
Material from a single colony from FAA was spotted on a MALDI-plate without 
pretreatment. The spots were then covered with 1µl matrix solution consisting of α-cyano-4-
hydroxycinnamic acid (HCCA) and left to air-dry in room temperature. The plate was then 
introduced into the MALDI-TOF mass spectrometer for analysis. The spectra of all isolates 
were compared to the spectra in the database and identification was provided with a score of 
reliability. A score <1.7 is considered an unreliable identification. A score ≥1.7 and <2.0 is 
considered a genus identification, however it is also considered an unreliable identification. 
Scores ≥2.0 were considered species-level identification. In those samples where MALDI-
TOF MS could not provide reliable results, or could not provide any results because the 
spectra did not exist in the database, the identification of the samples was carried out using 
16S rRNA gene sequencing described below.  
PCR 
All isolates to be 16S rRNA gene sequenced were prepared as boiled lysates. A 1µl plastic 
loop of colony material was washed in 200µl of phosphate buffered saline (PBS). The 
solution was vortexed until homogenous. It was then centrifuged for 5 min at 13,000 rpm. The 
liquid phase was discarded and the pellet dissolved in 200µl of new PBS-buffer. The solution 
was again centrifuged for 5 min at 13,000 rpm. After the liquid phase was discarded, 50 µl of 
DNase and RNase free water (Sigma Aldrich Company Ltd, Irvine, UK) was added to the 
pellet and vortexed. The solution was boiled in a heating block (98°C) for 10 min and then 
immediately cooled on ice for 10 min. The solution was then centrifuged for 10 minutes at 
13,000 rpm. The supernatant was transferred to a clean tube and the pellet discarded. As 
template for the PCR a 1/10 dilution of the supernatant was made. 
The PCR was performed using primers Bac27F (5’-AGAGTTTGGATCMTGGCTCAG-3’) 
and Univ1492R (5’-CGGTTACCTTGTTACGACTT-3’) (Jiang et al., 2006). A mastermix 
consisting of 21µl of DNase and RNase free water, 25 µl of Qiagen HotStarTaq® Master Mix 
(Qiagen, Hilden, Germany), 1 µl Bac27F primer and 1 µl Univ1492R primer was added to 2 
µl of template for a total volume of 50 µl. 16S rRNA gene amplification was then carried out 
as follows: initial heat-activation of the HotStar Taq® Master mix for 15 min at 95°C, 30 
cycles of denaturing (30 s at 95°C), annealing (30 s at 55°C), and extension (90 s at 72°C); 
and a final extension at 72°C for 10 min. To verify that the PCR was successful, gel-
electrophoresis in a 1.5% agarose gel was performed.  
16S r RNA gene sequencing 
Before sequencing the PCR product was treated enzymatically using FastAP™ 
Thermosensitive Alkaline Phosphatase (Thermo Scientific, Waltham, USA) and Exonuclease 
I E.coli (Thermo Scientific, Waltham, USA) according to the manufacturer’s description. The 
phosphatase inactivates unincorporated nucleotides. The nuclease digests single-stranded 
DNA. In our samples that means A-overhang on the PCR products and left-over primers. The 
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samples were loaded into the 2720 Thermal cycler (Applied Biosystems, Foster City, USA), 
heated to 37°C for optimal enzymatic activity for 15 minutes and then increased to 80°C for 
15 minutes to denature and thereby inactivate the enzymes. 
For the sequencing reaction the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, Foster City, USA) was used. Two master-mixes was prepared for each template 
by taking 2 µl of Terminator ready reaction mix (v3.1) and adding 1 µl of BigDye Sequencing 
buffer and 1 µl of either the Bac27F primer or the Univ1492R primer, each at a concentration 
of 10µM. Between 1-4 µl of each template was then added to their Master-mix depending on 
the concentration from the first PCR, interpreted by reading the intensity of the bands on (the) 
gel-electrophoresis. The templates with the Master-mix were then run through a new PCR 
according to the manufacturer’s description. 
The PCR products from the BigDye Terminator reaction was cleaned by solidifying the DNA 
by sodium acetate and ethanol and centrifugation. The resulting pellet was washed once with 
ethanol and thereafter dried at 50°C for 3 minutes. The DNA was dissolved in formamide and 
sequenced using the 3100 Genetic Analyzer (Applied Biosystems, Foster City, USA) 
according to the manufacturer’s protocol.  
Antimicrobial susceptibility tests 
All isolates were tested for antimicrobial susceptibility using VetMIC GP-mo (ver.2) 
microdilution plates (SVA, Uppsala, Sweden). The plates contain the following 
antimicrobials in the following ranges of concentration: penicillin (0.015-2 µg/ml), 
cephalothin (0.03-4 µg/ml), oxacillin +2% NaCl (0.06-8 µg/ml), erythromycin (0.125-16 
µg/ml), chloramphenicol (0.25-32 µg/ml), clindamycin (0.125-16 µg/ml), tetracycline (0.25-
32 µg/ml), fusidic acid (0.03-4 µg/ml), gentamicin (0.25-32 µg/ml), kanamycin (0.125-16 
µg/ml), ciprofloxacin (0.03-2 µg/ml), trimethoprim (0.25-16 µg/ml). The plate also contains a 
control well with a citrate buffer. No growth in this well will imply a sensitivity of the strain 
to the citric acid which is included in the buffer used in the wells with penicillin. In these 
cases reading the penicillin sensitivity is not possible. For the control of growth one well with 
only the bacterial suspension was included. The panel is not exclusively designed for isolates 
from horses and contains antimicrobials not intended for use in horses such as clindamycin. It 
also contains antimicrobials not readily available in suitable formulations in Sweden for use 
in horses such as chloramphenicol. However this panel was the best choice for this study 
because of the long penicillin range included. 
All but one (that was obtained late in the study) of the isolates identified as Bacteroides 
fragilis were because of resistance to many of the substances in the GP-mo panel tested on 
two additional panels, VetMIC Stordjur (SVA, Uppsala, Sweden) and VetMIC CLIN GN 
(SVA, Uppsala, Sweden). The VetMIC Stordjur panel is designed for bacteria isolated from 
horses but also from other animals such as cattle and pigs and therefore contains 
antimicrobials not used in horses in Sweden. The VetMIC CLIN GN is designed for use with 
Gram-negative bacteria and also contains antimicrobials not used in horses in Sweden. The 
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VetMIC Stordjur panel contains the following antimicrobials in the following ranges: 
penicillin (0.5-0.06 µg/ml), ampicillin (0.5-4 µg/ml), ceftiofur (0.125-1 µg/ml), spiramycin 
(2-16 µg/ml), neomycin (2-16 µg/ml), gentamicin (1-8 µg/ml), streptomycin (2-16 µg/ml), 
trimethoprim/sulphamethoxazol (0.25/4.75-2/38 µg/ml), enrofloxacin (0.06-0.5 µg/ml), 
oxitetracycline (0.5-4 µg/ml), florfenicol (1-8 µg/ml), oxacillin (0.25-0.5 µg/ml). The VetMIC 
CLIN GN panel contain the following antimicrobials in the following ranges: ampicillin (1-8 
µg/ml), cefotaxime (0.125-1 µg/ml), amoxicillin/clavulanic acid (2/1-16/8 µg/ml), colistin 
(0,5-4 µg/ml), nitrofurantoin (4-32 µg/ml), trimethoprim/sulphamethoxazole (0.25/4.75-2/38 
µg/ml), gentamicin (1-8 µg/ml), streptomycin (4-32 µg/ml), neomycin (2-16 µg/ml), 
tetracycline (1-8 µg/ml), enrofloxacin (0.06-2 µg/ml). Both panels include a citrate buffer 
control and a growth control.  
Isolates were tested according to the Clinical and Laboratory Standards Institute’s guidelines 
for antimicrobial susceptibility testing for anaerobic bacteria (CLSI M11-A8). The following 
procedure was used for all three different microtitre panels. For each sample, colony material 
was suspended in 2 ml of Brucella broth with hemin (5µg/ml) and vitamin K1 (1µg/ml) (SVA, 
Uppsala, Sweden). The turbidity of the suspensions was adjusted to be equivalent to a 0.5 
McFarland solution which corresponds to a concentration of approximately 1-5x108 CFU/ml. 
For inoculum density control viable counts of the type strain were made by taking 10 µl of the 
suspension and adding it to 10 ml of sterile saline and then taking 100 µl of this dilution and 
spreading it on an FAA plate. These plates were incubated in an anaerobic environment at 
37°C for 48 h.  
To get a final concentration of 1-5x105 CFU per well 150 µl of the suspended colony material 
was added to 15 ml of Brucella broth with hemin (5µg/ml) and vitamin K1 (1µg/ml) 
supplemented with 750 µl of lysed horse blood. Each well of the microtitre plate was 
inoculated with 100 µl of this dilution. All plates were incubated in an anaerobic environment 
at 37°C for 48 h before final reading. All isolates, except the one obtained late in the study, 
that were identified as B. fragilis with MALDI-TOF MS were tested as described above and 
additionally tested using Brucella broth stored at -20°C for 11 months. This was done to 
evaluate if broth could be stored frozen and then be used for antimicrobial susceptibility 
testing of Bacteroides spp. 
Final reading of Minimum Inhibitory Concentration (MIC) was performed using both a 
BIOMIC V3 96-well microdilution plate reader (Giles Scientific, Santa Barbara, CA, USA) 
and by manual visual reading. The MIC was determined to be the lowest concentration of an 
antimicrobial agent completely preventing visible growth. To make sure the suspension used 
in the microdilution plates was not contaminated, a culture was made on FAA agar from the 
very same suspension used in the microtiter plate, and incubated in an anaerobic environment 
at 37°C for 48 h.  
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β-lactamase production 
All samples were tested for β-lactamase production using CefinaseTM (CEF-F) paper discs 
(bioMérieux® sa, Lyon, France). These discs are impregnated with nitrocefin, a chromogenic 
β-lactam, which turns red when the β-lactam ring is broken by a β-lactamase. Colony material 
was rubbed onto a disc moistened with sterile water and a color change within 30 min was 
considered as positive. Bacteroides fragilis ATCC 25285 was used as a positive control. 
Accepted breakpoints for resistance 
The MICs were interpreted by using clinical breakpoints set by the CLSI (M11-A8, M100-
S23), EUCAST and SVA and are outlined in table 1. For some of the antimicrobials there is 
no breakpoint in either CLSI or EUCAST and in these cases the breakpoints have been set 
using the interpretive criteria used for the VetMIC panels designed by SVA (VetMIC 
Stordjur, VetMIC CLIN GN and VetMIC Smådjur). VetMIC Smådjur is a microdilution plate 
for isolates from dogs and cats. The accepted clinical breakpoints used are adapted for 
Bacteroides spp. isolated from humans since no complete guideline for anaerobic bacteria 
isolated from horses exists. Not all of the tested substances have accepted breakpoints. Table 
1 shows the clinical breakpoints available for the tested antimicrobials. Not all antimicrobials 
tested are included in this table as they are not relevant to this study. 
Table 1. Clinical MIC breakpoints for resistance for selected antimicrobials 
  CLSI EUCAST VetMIC 
Antimicrobial S|I|R S|R S|I|R 
Penicillin ≤0.5|1|>1 ≤0.25|>0.5   
Ampicillin ≤0.5|1|>1 ≤0.5|>2   
Amoxicillin-Clavulanic Acid     ≤8/4| - |>8/4 
Erythromycin     >4 
Chloramphenicol ≤8|16|>16     
Clindamycin ≤2|4|>4 < 4|>4   
Tetracycline ≤4|8|>8     
Fusidic Acid     ≤4| - |>4  
Gentamicin   
 
≤4|8|>8 (NR) 
Kanamycin NR NR NR 
Ciprofloxacin NR NR NR 
Trimethoprim NV  NV NV 
Cefotaxime   
 
≤0.25| - |>0.25 
Nitrofurantoin     ≤64| - |>64 
Trimethoprim/sulfamethoxazole     ≤0.5/9.5|1/19-4/76|>4/76 
Ceftiofur     ≤2| - |>2 
S: Sensitive, I: Intermediate, R: Resistant, 
NR: not relevant, because of limited or uncertain effect for treatment of anaerobic infections in general (see discussion) 
NV: No value available for trimethoprim only 
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Carbapenemase-production 
Strains of B. fragilis harboring a gene for carbapenemase production (cfiA) can be separated 
from other B. fragilis by their MALDI-TOF spectra (Wybo et al., 2011). In addition to the 
antimicrobial testing, the spectra generated by the MALDI-TOF MS from isolates identified 
as Bacteroides fragilis were sent to Åsa Johansson, Centrallasarettet in Växjö, for analysis to 
evaluate if they belonged to the cfiA positive cluster.  
Medical Records 
All available medical records have been reviewed for diagnosis, treatment and outcome to 
determine if the horses were treated with antimicrobials to which the isolate was susceptible. 
RESULTS 
Bacterial species identification 
Of the 31 isolates frozen and previously identified as Bacteroides spp., it was not possible to 
get a viable culture from 2 isolates. A total of 29 isolates were identified by MALDI-TOF MS 
and 16S rRNA gene sequencing. Isolates were identified as Bacteroides spp. (n=22) 
Parabacteroides distasonis (n=2), Prevotella spp. (n=3), Fusobacterium sp. (n=1), and 
Porphyromonas sp. (n=1). Table 2 shows the outcome of the MALDI-TOF and DNA 
sequencing for all isolates. A dendrogram from all spectra except one (Fusobacterium sp.) 
was created with the MALDI Biotyper software (Fig 1). It shows the relationship between the 
isolates. The isolates clustered together are assumed to be of the same species and not all 
isolates were therefore 16S rRNA sequenced. Interestingly the two Bacteroides 
thetaiotaomicron do not cluster together, and it was only possible to identify one using 
MALDI-TOF MS, the other was identified by 16S rRNA sequencing. Table 2 outlines the 
results of MALDI-TOF MS and 16S rRNA gene sequencing. Table 3 illustrates the number of 
each species identified. 
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Table 2. Results of identification with MALDI-TOF MS and 16S rRNA gene sequencing 
Isolate MALDI-TOF MS Score 16S rRNA Identification derived  from dendrogram* 
4528 Bacteroides fragilis 2.305 - 
 4533 Bacteroides fragilis 2.283 - 
 4666 Parabacteroides distasonis 2.383 - 
 4693 No reliable identification 1.328 Fusobacterium sp. 
 4704 Not viable - - 
 4713 No reliable identification 1.331 Prevotella dentasini 
 4764 No reliable identification 1.375 Porphyromonas spp. 
 4829 Bacteroides ovatus 2.172 - 
 4860 Bacteroides fragilis 2.279 - 
 4928 Bacteroides fragilis 2.392 Bacteroides fragilis 
 4930 Bacteroides fragilis 2.344 - 
 4963 No reliable identification 1.317 Prevotella sp. 
 4977 Bacteroides fragilis 2.293 - 
 4987 Bacteroides thetaiotaomicron 2.263 - 
 4999 No reliable identification 1.586 
 
Bacteroides heparinolyticus 
5039 No reliable identification 1.565 Bacteroides heparinolyticus 
 5135 No reliable identification 1.441 Prevotella sp. 
 5233 Parabacteroides distasonis 2.358 - 
 5393 Not viable - - 
 5421 No reliable identification 1.554 
 
Bacteroides heparinolyticus 
5677 No reliable identification 1.418 Bacteroides heparinolyticus 
 5712 No reliable identification 1.409 Bacteroides heparinolyticus 
 5742 Bacteroides fragilis 2.361 - 
 5743 Bacteroides pyogenes 2.225 - 
 5745 No reliable identification 1.359 Bacteroides thetaiotaomicron 
 5749 No reliable identification 1.443 
 
Bacteroides heparinolyticus 
5794 Bacteroides fragilis 2.4 - 
 5817 Bacteroides fragilis 2.358 - 
 5827 Bacteroides ovatus 2.221 - 
 5992 No reliable identification 1.47 Bacteroides heparinolyticus 
 88957 Bacteroides fragilis 2.301 - 
 ATCC 
25285 Bacteroides fragilis 2.376 - 
 *These isolates have been identified with the help of the dendrogram (Fig. 1). Isolates clustering together in the 
dendrogram are assumed to be of the same species as their spectra produced by the MALDI-TOF MS are very 
similar.  
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Fig 1. Dendrogram of spectra generated using MALDI-TOF MS. 
 
Table 3. Identified species 
Species N 
Bacteroides fragilis 10 
Bacteroides heparinolyticus 7 
Bacteroides ovatus 2 
Bacteroides thetaiotaomicron 2 
Bacteroides pyogenes 1 
Parabacteroides distasonis 2 
Prevotella sp. 2 
Prevotella dentasini 1 
Porphyromonas sp. 1 
Fusobacterium sp. 1 
Total 29 
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B. fragilis 4977
B. fragilis 4928
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B. fragilis 4528
B. fragilis 5817
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B. fragilis 5742
B. fragilis 5794
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B. pyogenes 5743
B. thetaiotaomicron 4987
B. thetaiotaomicron 5745
B. ovatus 5827
B. ovatus 4829
B. heparinolyticus 5677
B. heparinolyticus 5749
B. heparinolyticus 5992
B. heparinolyticus 5712
B. heparinolyticus 4999
B. heparinolyticus 5039
B. heparinolyticus 5421
Prevotella sp. 4963
Prevotella dentasini 4713
Prevotella sp. 5135
Porphyromonas sp. 4764
Parabacteroides distasonis 5233
Parabacteroides distasonis 4666
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All the isolates identified as B. heparinolyticus were prepared as ethanol extracts and sent to 
Bruker Daltonics to be included in the next version of their database. This will allow for 
future identification of this species with MALDI-TOF MS. 
Source of isolation 
The samples came from different sources. Table 4 summarizes the source of the samples from 
which they were isolated. The B. fragilis isolates came from a variety of sources whereas 5 of 
the 7 (71%) isolates of Bacteroides heparinolyticus came from infections involving the lower 
respiratory tract or paraoral infections. 
Table 4. Source of isolation  
Species Source of isolation N 
Bacteroides fragilis Abscess 5 
 
Wound 2 
 
Synovial fluid 1 
 
Peritoneal fluid 1 
 
Tracheal aspirate 1 
Bacteroides heparinolyticus Sinus 3 
 
Tracheal aspirate 1 
 
Bronchoalveolar lavage 1 
 
Wound 1 
 
Peritoneal fluid 1 
Bacteroides ovatus Abscess 1 
 
Uterus 1 
Bacteroides thetaiotaomicron Abscess 1 
 
Faecal sample 1 
Bacteroides pyogenes Wound 1 
Parabacteroides distasonis Blood 1 
 
Synovial fluid 1 
Prevotella sp. Wound 1 
 Tracheal aspirate 1 
Prevotella dentasini Peritoneal fluid 1 
Porphyromonas sp. Wound 1 
Fusobacterium sp. Fecal sample 1 
Total   29 
 
Antimicrobial susceptibility 
Table 5 illustrates the results of the antimicrobial susceptibility testing for a selection of the 
antimicrobials in the VetMIC GP-mo panel. 
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      Table 5. MIC of selected antimicrobials for the isolates  
    CLSI   S|I|R   ≤0.5|1|>1 ≤2|4|>4   ≤8|16|>16 ≤2|4|>4 ≤4|8|>8   N/R N/R N/R N/K 
    EUCAST      S|R   ≤0.25|>0.5       >4     N/R N/R N/R N/K 
    VetMIC   S|I|R       >4         N/R N/R N/R N/K 
  
 
Range µg/ml   0.015-2 0.03-4 0.125-16 0.25-32 0.125-16 0.25-32 0.03-4 0.25-32 0.125-16 0.03-2 0.25-16 
Isolate Source Species Cefinase Pc Ct Em Cm Cla Tc Fu Gm Km Ci Trim 
4528 Hoof-abscess B. fragilis pos >2 >4 16 8 1 0.25 >4 >32 >16 >2 >16 
4533 Hoof-abscess B. fragilis pos >2 >4 >16 8 1 1 >4 >32 >16 >2 >16 
4977 Synovia B. fragilis pos >2 >4 >16 8 0.5 32 >4 >32 >16 >2 >16 
5817 Abscess B. fragilis pos >2 >4 >16 8 0.5 1 >4 >32 >16 >2 >16 
4860 Peritoneal fluid B. fragilis Pos >2 >4 16 4 0.125 0.25 >4 >32 >16 >2 >16 
4928 Wound B. fragilis Pos >2 >4 16 4 1 0.25 >4 >32 >16 >2 >16 
4930 Wound B. fragilis Pos >2 >4 >16 8 0.5 0.5 >4 >32 >16 >2 >16 
5742 Hoof-abscess B. fragilis Pos >2 >4 >16 4 0.5 0.25 >4 >32 >16 >2 >16 
5794 Tracheal-aspirate B. fragilis Pos >2 >4 >16 8 0.5 0.5 >4 >32 >16 >2 >16 
B88957 Hoof-abscess B. fragilis Pos >2 >4 >16 8 2 0.5   >32 >16 2 >16 
4999 Tracheal-aspirate B. heparinolyticus Neg 0.12 1 1 4 0.125 0.25 0.5 >32 >16 >2 >16 
5421 Peritoneal fluid B. heparinolyticus Neg 0.06 1 1 2 0.125 0.25 0.5 >32 >16 >2 >16 
5677 Sinus B. heparinolyticus Neg 0.25 2 1 4 0.125 0.25 1 >32 >16 >2 >16 
5712 Sinus B. heparinolyticus Neg N/D 0.5 1 2 0.125 4 0.5 >32 >16 2 >16 
5749 Wound B. heparinolyticus Neg 0.03 0.5 0.5 2 0.125 0.25 0.5 >32 >16 2 >16 
5992 Sinus B. heparinolyticus Neg 0.25 0.5 1 4 0.125 0.25 1 >32 >16 >2 >16 
5039 BAL* B. heparinolyticus Neg N/D 0.5 0.5 4 0.125 0.25 1 >32 >16 >2 >16 
4829 Hoof-abscess B. ovatus Pos >2 >4 16 8 2 0.25 >4 >32 >16 >2 >16 
5827 Uterus B. ovatus Pos >2 >4 16 8 1 1 >4 >32 >16 >2 >16 
5743 Wound B. pyogenes Neg 0.03 0.25 0.5 1 0.25 0.25 0.5 >32 >16 0.5 >16 
4987 Fecal sample B. thetaiotaomicron Pos >2 >4 >16 8 4 0.5 >4 >32 >16 >2 >16 
5745 Abscess B. thetaiotaomicron Pos >2 >4 >16 8 16 0.25 >4 >32 >16 >2 >16 
ATCC 
25285   
B. fragilis Pos >2 >4 >16 8 0.5-2 0.25-
0.5 
>4 >32 >16 >2 >16 
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S: Sensitive, I: Intermediate, R: Resistant, 
N/D: Not determined 
N/R: not relevant, because of limited or uncertain effect for treatment of anaerobic infections in general 
N/K: No known clinical breakpoint available 
a. Lethal in horses – therefore not relevant 
Pc: penicillin, Ct: Cephalotin, Em: Erythromycin, Cm: Chloramphenicol, Cl: Clindamycin,  
Tc: Tetracycline, Fu: Fusidic Acid, Gm: Gentamicin, Km: Kanamycin, Ci: Ciprofloxacin, Trim: Trimethoprim 
*Bronchoalveolar lavage 
Table 6. MIC of selected antimicrobials against isolates not identified as Bacteroides spp. 
    CLSI   S|I|R   ≤0.5|1|>1 ≤2|4|>4   ≤8|16|>16 ≤2|4|>4 ≤4|8|>8       N/R N/K 
    EUCAST      S|R   ≤0.25|>0.5       >4         N/R N/K 
    VetMIC   S|I|R       >4         ≤2|4|>4   N/R N/K 
    Range µg/ml   0.015-2 0.03-4 0.125-16 0.25-32 0.125-16 0.25-32 0.03-4 0.25-32 0.125-16 0.03-2 0.25-16 
Isolate Source Species Cefinase Pc Ct Em Cm Cla Tc Fu Gm Km Ci Trim 
4693 Fecal sample Fusobacterium sp. Neg 0.25 0.5 >16 1 0.125 0.25 2 >32 >16 1 >16 
4666 Synovia Parabacteroides distasonis Neg >2 >4 >16 8 8 16 4 >32 >16 >2 >16 
5233 Blood Parabacteroides distasonis Neg >2 >4 >16 8 8 16 >4 >32 >16 >2 >16 
4764 Wound Porphyromonas sp. Neg 0.015 0.5 0.125 1 0.125 0.25 0.12 1 >16 1 >16 
4963 Wound Prevotella sp. Neg 0.015 0.03 0.125 1 0.125 0.25 0.12 4 >16 0.5 >16 
4713 Peritoneal fluid Prevotella dentasini Neg 0.015 0.06 0.25 2 0.125 0.25 1 >32 >16 2 8 
5135 Tracheal-aspirate Prevotella sp. Neg 0.015 0.5 4 2 0.25 0.25 0.25 >32 >16 2 >16 
S: Sensitive, I: Intermediate, R: Resistant 
N/R: not relevant, because of limited or uncertain effect for treatment of anaerobic infections in general 
N/K: No known clinical breakpoint available 
a. Lethal in horses – therefore not relevant 
Pc: penicillin, Ct: Cephalotin, Em: Erythromycin, Cm: Chloramphenicol, Cl: Clindamycin, 
Tc: Tetracycline, Fu: Fusidic Acid, Gm: Gentamicin, Km: Kanamycin, Ci: Ciprofloxacin, Trim: Trimethoprim
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Table 7 illustrates the results for all B. fragilis for selected antimicrobials from the CLIN GN 
and VetMIC Stordjur panels.  
Table 7. MIC of Bacteroides fragilis tested on CLIN GN and VetMIC Stordjur panels. 
  CLSI   S|I|R ≤0.5|1|>1 ≤4/2|8/4|>8/4     ≤0.25|-|-   
  EUCAST      S|R ≤0.5|>2           
  VetMIC   S|I|R     ≤64|-|>64 ≤0.5/9.5|-|>0.5/9.5     
  Range µg/ml 1-8 2/1-16/8 4-32 2.25/4.75-2/38 0.125-1 1-8 
Isolate Source Am A/C Ni T/S Ce Ff 
4528 Abscess >8 4/2 8 >2/38 >1 2 
4533 Abscess >8 4/2 8 >2/38 >1 4 
4977 Synovia >8 4/2 8 >2/38 >1 >8 
5817 Abscess >8 4/2 8 2/38 >1 4 
4860 Peritoneal fluid >8 4/2 8 >2/38 >1 2 
4928 Wound >8 8/4 8 >2/38 >1 2 
4930 Wound >8 4/2 16 >2/38 >1 4 
5742 Hoof-abscess >8 4/2 8 >2/38 >1 4 
5794 Tracheal-aspirate >8 4/2 8 2/38 >1 4 
S: Sensitive, I: Intermediate, R: Resistant 
Am: Ampicillin, A/C: Amoxicillin/Clavulanic Acid, Ni: Nitrofurantoin,  
T/Trimethoprim/sulfamethoxazole, Ce: Ceftiofur, Ff: Florfenikol 
 
It is important to note that the antimicrobial testing for B. heparinolyticus contains an error for 
two isolates. Isolate 5712 and 5039 were sensitive to the tri-cit buffer used in the penicillin 
wells. Therefore, it is not possible to draw conclusions about the MIC of penicillin for these 
two isolates. The remaining B. heparinolyticus showed growth in the tri-cit wells and the MIC 
of penicillin was assumed to be correct. 
Some isolates appear to be more resistant than others such as 4677 (B. fragilis) which 
demonstrates a much higher MIC of tetracycline than the other B. fragilis. Also, both P. 
distasonis isolates were more resistant than other isolates showing resistance to both 
clindamycin and tetracycline. 
Not all of the antimicrobials tested are displayed. One of the reasons for this being that some 
of the antimicrobials are only included in the VetMIC panels to identify specific bacteria. For 
example, oxacillin is included in the panels to identify methicillin resistant Staphylococcus 
aureus (MRSA). Therefore those results are not relevant to this study. Other antimicrobials 
have been included, even though they are not used in horses. This is because of potential 
value for other species of animals with Bacteroides spp. infections. Clindamycin is lethal in 
horses but is used in for example dogs. The results reflect that Bacteroides sp. are sensitive to 
clindamycin and so the results for this antimicrobial have value in being included. As are 
results for nitrofurantoin, it is an antimicrobial used off-label in dogs. Kanamycin is an 
aminoglycoside just like gentamicin. It have been included to demonstrate the general lack of 
susceptibility of Bacteroides spp. to aminoglycosides, even though kanamycin is not used in 
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horses in Sweden. Also, resistance to gentamicin does not automatically mean isolates will be 
resistant to kanamycin. Ciprofloxacin is included in the results even though no approved 
pharmaceutical exists for use in horses in Sweden. It is approved for use in humans and is 
used off-label in small animals. 
β-lactamase production 
All of the B. fragilis isolates were positive for β-lactamase production on the Cefinase™ 
nitrocefin discs whereas all of the Bacteroides heparinolyticus isolates were negative for β-
lactamase production. Also a much lower MIC for penicillin (≤0,015-0,25 µg/ml) was 
recorded for the B. heparinolyticus isolates compared to B. fragilis ( >2 µg/ml) and would be 
considered susceptible. All other Bacteroides spp. isolates identified, apart from one isolate of 
B. pyogenes, were positive for β-lactamase production and the MICs of penicillin were high 
(MIC >2 µg/ml). Interestingly, the two isolates identified as P. distasonis do not display β-
lactamase production, but still the MIC of penicillin were high (MIC >2 µg/ml).  
Frozen Brucella broth 
The isolates of B. fragilis that were run on the VetMIC GP-mo panels using frozen Brucella 
broth gave corresponding results to results using fresh Brucella broth. 
Carbapenemase-production 
All MALDI-TOF MS spectra sent to Åsa Johansson at Centrallasarettet in Växjö belonged to 
the cfiA negative group of B. fragilis.  
Medical Records 
No general conclusions can be drawn from the medical records as the quality of the 
information varies. It was not possible to obtain the medical records for two horses. It is clear 
that horses have been treated with antimicrobials to which the isolate is resistant. Table 8 
summarizes the medical records. For some isolates, the same antimicrobial will appear more 
than once in the treatment column. This means the horse has been treated more than once with 
the antimicrobial and has either been reexamined, readmitted or has changed treatment 
protocol. It is also possible that the route of administration has been altered, in which case this 
is indicated with intravenous (i.v.) or intramuscular (i.m.). 
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Table 8. Summary of antimicrobial treatment and duration of treatment obtained from the medical records 
Isolate Species identified Diagnosis Treatment Days treated Outcome 
4528 Bacteroides fragilis Hoof abscess Penicillin (i.v) Unknown Recovered 
4533 Bacteroides fragilis Hoof abscess unknown Unknown Unknown 
4666 Parabacteroides distasonis Synovitis Penicillin (i.v) 11 Unknown 
      Gentamicin (i.v) 15   
      Penicillin (i.m) 12   
4693 Fusobacterium sp. Colic unknown Unknown Recovered 
4977 Bacteroides fragilis Synovitis and osteomyelitis Penicillin (i.v) Unknown Euthanized 
      Gentamicin (i.v) Unknown   
5817 Bacteroides fragilis Perianal abscess Penicillin (i.m) 6 Recovered 
      Penicillin (i.v) 4   
4713 Prevotella dentasini Peritonitis Penicillin (i.v) 2 Euthanized 
      Gentamicin (i.v) 2   
4764 Porphyromonas sp. Hoof-abscess with involvement of distal phalanx Penicillin (i.v) 27 Recovered 
      Gentamicin (i.v) 21   
      Compress with Fucidic Acid Unknown   
      Trimethoprim/Sulfadiazine (p.o) 8   
4829 Bacteroides ovatus Hoof abscess Unknown Unknown Unknown 
4860 Bacteroides fragilis Peritonitis Penicillin (i.v) 30 Recovered 
      Gentamicin (i.v) 6   
4928 Bacteroides fragilis Fistula formation after apical tooth root abscess Unknown Unknown Recovered 
4930 Bacteroides fragilis Sutureline infection after surgery Penicillin (i.v) 26 Recovered 
      Gentamicin (i.v) 10   
4963 Prevotella sp. Funiculitis Penicillin (i.m) 15 Recovered 
      Trimethoprim/Sulfadiazine (p.o) 14   
      Penicillin (i.v) 13   
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4987 Bacteroides thetaiotaomicron Right dorsal colitis caused by NSAID treatment No antimicrobial treatment   Euthanized 
4999 Bacteroides heparinolyticus Pleuropneumonia (esophageal obstruction) Gentamicin (i.v) Unknown Euthanized 
      Penicillin (i.v) 4   
      Ceftiofur 1   
      Metronidazole Unknown   
5039 Bacteroides heparinolyticus Unknown Unknown Unknown Unknown 
5135 Prevotella sp. Pleuropneumonia (esoophageal obstruction) Penicillin (i.m) 8 Unknown 
5233 Parabacteroides distasonis Purulent artrit och sepsis Penicillin (i.v) 10 Euthanized 
      Trimethoprim/Sulfadiazine (i.v) 7   
      Amikacin (i.a) 1   
      Gentamicin (i.v) 4   
5421 Bacteroides heparinolyticus Peritonit Penicillin (i.v) 15 Recovered 
      Gentamicin (i.v) 12   
5677 Bacteroides heparinolyticus Sinusitis (apical tooth root abscess) Penicillin (i.v) 9 Recovered 
      Penicillin (i.v) 7   
      Trimethoprim/Sulfadiazine (p.o) 12   
5712 Bacteroides heparinolyticus Sinusitis Penicillin (i.v) 16 Recovered 
      Gentamicin (i.v) 15   
5742 Bacteroides fragilis Hoof-abscess Penicillin (i.v) 15 Recovered 
      Trimethoprim/Sulfadiazine (p.o) 11   
5743 Bacteroides pyogenes Wound infection Penicillin (i.m) 6 Recovered 
      Trimethoprim/Sulfadiazine (p.o) 6   
      Medicinal honey Unknown   
      Penicillin (i.v) 7   
      Penicillin (i.m) 5   
      Penicillin (i.v) 8   
5745 Bacteroides thetaiotaomicron Abscess Unknown Unknown Unknown 
5749 Bacteroides heparinolyticus Septic arthritis Trimethoprim/Sulfadiazine (p.o) 8 Recovered 
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      Penicillin (i.m) 3   
      Penicillin (i.v) 11   
      Gentamicin (i.v) 8   
5794 Bacteroides fragilis Pleuritis following esophageal rupture Penicillin (i.v) 3 Euthanized 
      Gentamicin (i.v) 3   
5827 Bacteroides ovatus Chronic endometritis Penicillin (i.m) 5 Unknown 
5992 Bacteroides heparinolyticus Sinusitis Penicillin (i.v) 4 Euthanized 
      Penicillin (i.m) 11   
B88957 Bacteroides fragilis Hoof-abscess Penicillin (i.v) 5 Euthanized 
 
 
 
24 
 
DISCUSSION 
Even though infection with Bacteroides spp. can be severe, the treatment is seldom guided by 
results of susceptibility testing as it is not routinely performed. This could be potentially life-
threatening as we in this study have seen that isolates of B. fragilis are resistant to penicillin, a 
frequently used antimicrobial in Sweden. It is important to note when reading antimicrobial 
susceptibility reports and studies that the anaerobes are frequently grouped into one category, 
and general statements are made about their susceptibility. This has consequences as it might 
lead clinicians to believe that all anaerobes are sensitive to for example penicillin, when in 
fact several members of Bacteroides spp. are resistant. When the anaerobes are separated, it is 
usually into genus. This is also misleading, with the results of this study indicating that 
different species within the same genus have different susceptibilities. 
As described in the literature review, Bacteroides spp. are important in infections in horses 
and it is important to know their antimicrobial susceptibility to start correct treatment as soon 
as possible. This again places emphasis on the importance that the clinician knows the correct 
technique for sampling and on the importance of requesting anaerobic cultures and 
antimicrobial susceptibility tests for the anaerobes. If all horses with infections, in which 
anaerobes could be suspected, were tested for anaerobic isolates then perhaps more horses 
would receive correct treatment. This is well demonstrated by Mair & Lane (1989) in a 
review of horses with lung abscesses and primary pneumonia. Only samples from 6 of 11 
horses were cultured anaerobically and 3 of these 6 cultures (50 %) were positive for 
anaerobic growth. All of these returned at least one Bacteroides spp. This might well mean 
that several of the horses not tested for anaerobic isolates had anaerobic infections and might 
therefore have received incorrect treatment. 
Identification 
The use of MALDI-TOF MS in species-identification of bacteria will notably speed up the 
identification-process and also reduce costs incurred by the laboratory. The strains identified 
as B. heparinolyticus has been prepared as ethanol extracts and sent to Bruker Daltonics for 
incorporation into their new database. Because of this study it will now be possible to identify 
B. heparinolyticus using MALDI TOF MS. The percentage of isolates successfully identified 
using MALDI-TOF MS in this study was 55% (16/29). With the addition of Bacteroides 
heparinolyticus to the software it would then be possible to identify 79% (23/29) of isolates in 
this study. With the upgraded database, and when excluding the isolates incorrectly identified 
as Bacteroides spp., the software will be able to identify 95% (21/22) of the Bacteroides spp. 
isolates in this study. With the exception of one isolate of B. thetaiotaomicron all isolates 
ultimately identified as Bacteroides spp. in this study could be identified using the MALDI-
TOF MS. 
Of interest to note is the identification of isolates as Bacteroides spp. when they are in fact 
Prevotella spp., Parabacteroides spp., and Porphyromonas spp. However, they were up until 
recently part of the Bacteroides genus and are most likely very similar in their phenotypic 
profile, and so it might be impossible to identify these correctly using more traditional 
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methods. One isolate was found to be an unnamed Fusobacterium sp. which is also a Gram-
negative genus and which include species that may phenotypically resemble Bacteroides spp. 
By using MALDI-TOF MS to identify isolates it will be possible to reduce the risk of 
incorrect identification in the future.  
Source of isolation 
It is interesting to note that 5/7 (71%) of the isolates identified as Bacteroides heparinolyticus 
came from paraoral or lower respiratory tract infections. A search for B. heparinolyticus in 
animals in databases reveals that they are commonly found in the oral cavity which would 
explain their involvement in these types of infections (Bailey & Love, 1991). Careful 
speculation can be made that paraoral and respiratory tract infections will have a higher 
incidence of B. heparinolyticus involved whereas abscesses and wounds will have a higher 
incidence of B. fragilis because of contamination from the fecal flora. Of the 5 isolates which 
came from hoof abscesses, 4 of these (80%) were identified as B. fragilis. One isolate which 
came from an abscess could not be closer source-identified as the medical record was never 
obtained. This isolate is nevertheless identified as B. fragilis which makes involvement of B. 
fragilis in abscesses in this study 5/6 (83%). This can be important information to clinicians 
as early conclusions about the susceptibility can be made when culture results are reported 
before susceptibility results arrive. The results in this study indicate that B. heparinolyticus 
are susceptible to penicillin and B. fragilis are resistant. And perhaps tentative suggestions 
can be made that when Bacteroides spp. are involved in lower respiratory tract infections they 
are likely to be susceptible to penicillin whereas when they are involved in abscesses or 
wounds they are more likely to be resistant against penicillin. 
Antimicrobial susceptibility 
It is important to remember that the results found in this study are in vitro results obtained 
under controlled laboratory conditions. It is not guaranteed that an antimicrobial will behave 
and have the same effect in vivo as the condition at a site of infection is different. Clinical 
results are dependent on many different host factors such as anatomy, physiological and 
pathological barriers, different bacterial properties and pharmacokinetic and 
pharmacodynamic properties such as volumes of distribution, protein-binding and attainable 
tissue concentrations. If it is not possible to achieve the concentration required at the site of 
infection the treatment with antimicrobials will not be successful. For example, the ability of 
Bacteroides spp. to harvest thymidine from its surroundings in a necrotic process will render 
trimethoprim-sulfonamides useless in an in vivo situation, even if the in vitro results are 
promising (Indiveri & Hirsh, 1992). This difference between in vitro and in vivo results is 
demonstrated in two early case reports using metronidazole in horses with pleuropneumonia, 
that even though the organisms were sensitive to the previous antimicrobials used, the horses 
did not improve until an additional antimicrobial was used (Mair & Yeo 1987). It is also 
pertinent to remember that not all infections involve one single agent, but infections are 
usually mixed. This would mean that whilst one bacterial species shows resistance, the other 
involved organisms might be susceptible. It is important that the clinician bears this in mind. 
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Also, it is important to remember that currently no susceptibility testing is done for 
Bacteroides spp. which would give a false indication of susceptibility in a mixed sample 
where the other infecting organisms are susceptible to certain antimicrobials. This might lull 
the clinician into a false sense of security which might lead to the withdrawal of certain 
antimicrobials, possibly effective against Bacteroides spp., from the treatment regime. 
To determine if an antimicrobial will be effective against an organism in vivo the clinician 
needs to take into consideration more than just the results of susceptibility testing. 
Pharmacokinetic and pharmacodynamic properties needs to be considered for each 
pharmaceutical and the doses recommended. Unfortunately, not all antimicrobials will have 
detailed information on their behavior in tissues and distributions to sites of infection in 
horses. Table 9 outline pharmacokinetic data for some of the most commonly used 
antimicrobials in horses in Sweden. These are serum levels of the antimicrobial. With this 
information, visualization of the problems facing the clinician becomes easier to understand. 
It is not possible to maintain concentrations required for certain antimicrobials to be effective 
over extended periods of time. And although the concentrations required for inhibition of 
bacterial growth might seem achievable, the quick half-lives of most antimicrobials bring 
plasma levels down to concentrations too low to be considered effective. However, it is 
important to remember; that for some antimicrobials, whilst the concentration in plasma is 
low, the distribution of the antimicrobial into tissues and transcellular spaces such as the 
peritoneal fluid might be higher, as demonstrated by Sweeney et al. (1986) in regards to 
metronidazole. The study shows that metronidazole reaches even higher levels in peritoneal 
fluid than in serum when given intravenously or orally. Because it is a lipophilic weak base it 
penetrates cell membranes very well, allowing for good distribution in tissues (Dowling, 
2013). So there are many factors influencing the effectiveness of the antimicrobials. 
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Table 9. Pharmacokinetics data in horses for relevant antimicrobials from selected references 
Antimicrobial Dose (unit) Route of 
administration 
Cmax (μg/ml) (hours 
after administration) 
Half-life (h) Conc(μg/ml ) (hours 
after administration) 
Reference 
Benzylpenicillin sodium 20,000( IU/kg) 
20.000 (IU/kg) 
iv 
im 
>40 (0.25) 
>10 (0.25-0.5) 
0.8 
1.5 
0.5 (2.92) 
0.5 (6.2) 
Love et al., 1983  
Love et al., 1983  
Procaine-benzylpenicillin 20,000 (IU/kg) 
22,000 (IU/kg) 
im 
im 
~1.5 (1) 
2.06 (4) 
19.68 0.5 (18.75) 
0.17(24) 
Love et al., 1983,  
Sullins et al., 1984 
Gentamicin 6.6 (mg/kg) iv 71.9±15.7 3.0±2.8 22.0±4.9 (1.31), 
 1 (~11) 
Magdesian et al., 1998 
Trimethoprim/Sulfadiazine 2.5(mg/kg)/12.5(mg/kg) 
5 (mg/kg)/25(mg/kg) 
iv 
po 
2.42/52.7 
1.06/22.4 
2.8/4.6 
5.1/8.2 
 Gustafsson et al., 1999 
Gustafsson et al., 1999 
Ceftiofur       
Oxitetracycline 10( mg/kg) Iv 135.1±21.0 12.95 >1 μg/ml (36) Horspool & McKellar, 
1990 
Metronidazole 20(mg/kg), 
25(mg/kg) 
po 
po 
22±8 (~1) 
12.6±2.4 (1-2) 
3.5±0.5 
2.5 
~1 (13.3) 
~2 (10) 
Steinman et al., 2000 
Sweeney et al., 1986 
. 
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Studies have shown that not all Bacteroides strains produce β-lactamases but are still resistant 
to penicillin showing that these bacteria have some alternative mechanism for penicillin 
resistance (Fang et al., 2002). This means that testing for β-lactamase production only is not 
enough to determine if the patient can be treated using penicillin in the case of Bacteroides 
infections. However it is a quick test to determine the β-lactamase production from bacteria 
and penicillin can quickly be ruled out as a treatment option in a positive test. It cannot 
however be assumed that the infecting organism will be susceptible in a negative test result. 
In this study, only the P. distasonis displayed a negative result for β-lactamase production but 
were still resistant against penicillin. The results indicated that all of the Bacteroides spp. 
isolates in this study with β-lactamase production are highly resistant to penicillin. A 
promising result of the study is that the nitrocefin disc test can be performed early in the 
identification of the isolates as minimal colony material is required for this test. This would 
quickly give indications about the susceptibility of the isolate to penicillin. 
Penicillin would appear to be a poor choice of antimicrobial in infections with B. fragilis, B. 
thetaiotaomicron and B. ovatus as they in this study show resistance to penicillin because of 
β-lactamase production. However, it might be efficient in infections involving B. 
heparinolyticus or B. pyogenes as they do not demonstrate β-lactamase production and have a 
lower MIC for penicillin in this study. Penicillin is the first-choice antimicrobial in Sweden 
and most horses are initially treated with this. Therefore, using the β-lactamase test in 
conjunction with species identification by MALDI-TOF MS and antimicrobial susceptibility 
testing can quickly rule it in or out for treatment of infections. When combining 
pharmacokinetic studies and the MIC values obtained in this study, it is clear that it is not 
possible to achieve effective concentrations of penicillin in the horse against B. fragilis, B. 
thetaiotaomicron and B. ovatus. However, for B. heparinolyticus and B. pyogenes, which 
have considerably lower MIC for penicillin, it is a good choice of antimicrobial. As seen in 
this study the MIC for B. heparinolyticus and B. pyogenes is below or equal to the 0.25 µg/ml 
clinical breakpoint set by EUCAST and well below the 0.5 µg/ml clinical breakpoint set by 
the CLSI. At the recommended dose of 22.000 IU/kg given once or twice intramuscularly the 
concentration of penicillin in the horse stays above the clinical breakpoints for extended 
periods of time and well above the MIC for B. heparinolyticus and B. pyogenes which makes 
it a very suitable antimicrobial for treatment of these infections in horse (Sullins et al., 1984; 
Love et al. 1983). 
Gentamicin is approved for use in horses in Sweden; however, it was shown early that 
aminoglycosides such as gentamicin and kanamycin are relatively ineffective against 
anaerobes, requiring over ≥128 μg/ml to inhibit 50% of isolates (Kimsey & Hirsh 1978). 
None of the aminoglycosides tested (gentamicin, kanamycin, streptomycin) were effective 
against the 29 isolates of Bacteroides spp. This would be expected given that aminoglycosides 
cannot function in an anaerobic environment since uptake of the antimicrobial is oxygen-
dependent. However, as gentamicin is the antimicrobial used most frequently in conjunction 
with penicillin in horses it was considered relevant to present data that supports it has no 
effect on Bacteroides spp.  
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Tetracycline showed promising effect against all but two of the isolates. However, given the 
high risk of side-effects such as enterocolitis it would not be wise to recommend this 
antimicrobial to be used in horses for extended periods of time. Also, horses treated with 
tetracycline need to be carefully monitored for signs of developing colitis. Currently there is 
no authorized tetracycline antimicrobial in Sweden and use is off-label.  
Cephalotin showed promising in vitro results against B. heparinolyticus and the one isolate of 
B. pyogenes. Unfortunately B. fragilis and the remaining Bacteroides spp. in this study 
showed resistance against this substance. Since B. heparinolyticus and B. pyogenes are both 
susceptible to penicillin it means there is no need to use cephalosporins in the treatment of 
Bacteroides spp. infections in the horse.  
Ceftiofur was only tested on B. fragilis in this study, and all isolates showed resistance. 
Hence, ceftiofur is a poor choice of antimicrobial for isolates of Bacteroides spp. with β-
lactamase production. Interestingly, one study comparing anaerobic equine isolates to bovine 
isolates and their susceptibility to ceftiofur found a higher rate of resistance in equine isolates 
(Samitz et al., 1996). 
All isolates were tested against trimethoprim, but only B. fragilis was tested against a 
combination of trimethoprim and sulfonamides. Both of these compounds have been 
determined to be more efficient against anaerobes when combined in animals (Indiveri & 
Hirsh 1986). However in necrotic tissues and exudates the thymidine content may inhibit the 
effect (Indiveri & Hirsh, 1992) and the outcome of the treatment is uncertain. Approved 
substances for intravenous and oral administration are available for horses in Sweden.  
Unfortunately we were not able to test the isolates against metronidazole, but other studies 
show that there is currently very little resistance among Bacteroides spp. to metronidazole 
even globally and in humans (Ulger-Toprak et al., 2004; Aldridge et al., 1994; 2001; Nagy et 
al., 2010; Jousimies-Somer et al., 2003; Hirsh et al., 1985) and it would be an effective 
alternative for treatment of these infections in horses. However, metronidazole does not exist 
on the market specifically for horses or other animals in Sweden, and the off-label use of 
drugs intended for humans quickly gets expensive because of the large dosages required. 
Metronidazole has a high bioavailability when given orally, up to 85%, and penetrates bone, 
abscesses and the central nervous system well (Dowling, 2013). Metronidazole shows a very 
good distribution to peritoneal fluid in horses which would make it an ideal pharmaceutical to 
treat horses with peritonitis involving anaerobic organisms resistant to other antimicrobials 
available. The clinical breakpoint for resistance in Bacteroides spp. is frequently reported as 
>16μg/ml (Lawhon et al., 2013; Nagy et al., 2010; Aldridge et al., 1994; Hirsh et al., 1985), 
although EUCAST uses ≤4 μg/ml (sensitive) and >4 μg/ml (resistant). The MIC of 
Bacteroides spp. isolated from animals is reported by Lawhon et al. (2013) to be <1.5 μg/ml, 
and over 85 % have a MIC of ≤0.75 μg/ml. The pharmacokinetic data shows that the level of 
metronidazole stay well above this for at least 13 hours (Steinman et al., 2000; Sweeney et 
al., 1986). A large study spanning 20 years of research reported the MIC90 for Bacteroides 
spp. to be 1-2 μg/ml (Nagy et al., 2010). 
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One of the earliest reports of metronidazole used in two horses with pleuropneumonia 
demonstrates improvement when given metronidazole intramuscularly after being treated for 
prolonged periods with both penicillin and trimethoprim-sulphadoxine. Susceptibility test 
revealed however that all the isolates, including four Bacteroides spp. isolates, were sensitive 
to both penicillin and trimethoprim-sulphadoxine (Mair & Yeo 1987). This demonstrates that 
although an organism might be sensitive in vitro to a pharmaceutical it might not be effective 
in vivo. And although it is not possible to attribute the successful outcome in these two cases 
only to the use of metronidazole, it suggests that it played a role in the recovery of the horses 
since they had both been treated for prolonged periods with other antimicrobials without 
improvement.  
The isolates identified as Parabacteroides distasonis showed significant resistance to many of 
the antimicrobials tested. The only antibiotic to which they appear to be susceptible is 
chloramphenicol. This is not readily available in Sweden other than in ophthalmic solutions. 
It would pose quite a problem when deciding which antimicrobial to use. One of these isolates 
came from the synovial fluid from a foal which suffered from sepsis and septic arthritis. The 
foal was euthanized after failure to respond to treatment. See case 2 under medical records 
below. 
Developing new methods for susceptibility testing 
Using Brucella broth frozen 8 months previous to this study was done in an attempt to 
determine whether it is possible to do antimicrobial testing for Bacteroides spp. using frozen 
broth. The fresh broth used in these trials is not readily available and must be ordered 
specifically for every occasion. This is time consuming and delays the process of 
antimicrobial testing. It might also be one explanation as to why susceptibility testing is not 
currently performed for Bacteroides spp. The results reflect that using frozen broth works 
very well and the results for B. fragilis antimicrobial susceptibility test are the same for both 
fresh and frozen broth. This means the laboratory could use frozen broth and speed up the 
process of antimicrobial susceptibility testing. Using frozen broth would most likely prove 
both time and cost effective. 
Medical Records 
As previously stated, it is not possible to draw general conclusions from the medical records 
as the quality varies amongst them and because of the insufficient number of samples 
included in this study. Also it was not possible to obtain all records. It is however worth 
noting that several of these cases were treated with antimicrobials to which the isolated 
organism was resistant.  
Case 1 – 4930 
A horse developed a subcutaneous infection in the suture line after an exploratory laparotomy. 
It was found that the horse had nephrosplenic entrapment of the colon with a complete 
retroflexion of the pelvic flexure. An enterotomi was performed to empty the large colon of 
its contents. The horse was treated with penicillin, gentamicin and flunixin-meglumine. The 
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horse recovered well from the surgery and the incision and suture line looked good with no 
signs of infection. However, the horse started to develop pain upon inspection of the suture 
line and eventually developed a mild ventral edema along the suture line. Ultrasound revealed 
a small collection of fluid in the caudal end of the suture line. A few staples were removed to 
obtain a culture. However, no visual signs of infection besides the ventral edema and pain 
were present. The first visual signs were seen six days after the surgery when a small 
collection of pus was seen in the suture line. The horse was still undergoing medication with 
penicillin and gentamicin. 
The Laboratory reported growth of Bacteroides spp. and the horse was sent home with 
treatment with intramuscular procaine-penicillin and daily cleaning of the wound. However, 
the horse continued experiencing discomfort and pus started to drip from the suture line. The 
horse was returned to the clinic for assessment and continuing i.v. medication with penicillin. 
The horse recovered after being treated with penicillin for 26 days, including 10 days with 
gentamicin, and daily cleaning of the wound. Our results show that this horse had an infection 
with B. fragilis not susceptible to penicillin or gentamicin. If susceptibility tests had been 
performed perhaps a more suitable treatment could have been initiated. One can speculate that 
the recovery of the horse might more be attributed to the constant cleaning of the wound than 
the antimicrobial treatment received. 
Case 2 - 5233 
A 3 week old foal was treated for sepsis and purulent arthritis in the right tarsal joint. The foal 
was treated with an intravenous dose of plasma, penicillin and trimethoprim-sulfonamides, 
along with flunixin-meglumine, omeprazole, vitamin-K and intravenous fluids. Synovia was 
collected for analysis and amikacin deposited locally in the joint. The joint was also flushed. 
Laboratory results showed infection with Bacteroides spp. At first the foal started to recover 
and showed signs of improvement. The foal was assessed to be well enough to be sent home 
and about to be discharged when it suddenly started to swell up in the other tarsal joint. The 
foal underwent flushing of both tarsal joints under general anesthesia and the medication was 
supplemented with gentamicin. The general condition of the foal was good, but the joints 
continued to swell and an increasing lameness was seen. Eventually both the carpal joints also 
showed signs of involvement and the decision was made to euthanize the foal. 
The isolate was identified in this study as Parabacteroides distasonis. This is an example of 
where antimicrobial susceptibility testing could have increased the chances for this foal. 
According to our results, this isolate was resistant to penicillin, trimethoprim and gentamicin. 
Treatment with metronidazole could have been effective, however since the isolate has not 
been tested against metronidazole it is only possible to speculate.  
CONCLUSION 
This study demonstrates the importance of antimicrobial susceptibility testing. The 
recommendation would be to initially test isolates of genus Bacteroides for β-lactamase 
production using the nitrocefin discs. This is a quick test which immediately lets you know if 
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the Bacteroides spp. involved in the infection will be resistant to penicillin and an alteration in 
treatment could be quickly implemented whilst waiting for results of broader antimicrobial 
susceptibility testing. If the isolate is found to be β-lactamase producing then the 
recommendation is to use antimicrobials other than penicillin. 
Unfortunately it would appear that there are very few treatment options available for the most 
resistant of strains of B. fragilis as not all antimicrobials are readily available in suitable 
formulations in Sweden. Also, the antibiotics that are available such as tetracycline are used 
only in rare cases of disease, being currently only recommended for treatment of 
anaplasmosis and Lawsonia intracellularis infections. Tetracycline has a high risk of side-
effects such as enterocolitis which would make it an unsuitable antimicrobial for use over 
extended periods of time. Chloramphenicol does not exist in the formulation required for 
treatment of infections from which these samples have come. In Sweden, chloramphenicol is 
available for ophthalmic infections only. Clindamycin appears to be effective; however this 
antimicrobial is lethal in horses and cannot be used. It is however useful in other species such 
as dogs, and the results in this study might help clinicians when dealing with patients other 
than horses. 
If it is a serious case with a rapidly deteriorating patient, metronidazole should be considered 
to be included in the treatment regimen because of its effect on anaerobes. Unfortunately we 
were not able to test the susceptibility of our isolates against metronidazole, but other studies 
show that metronidazole is efficient against Bacteroides spp. and this should be considered as 
a treatment option in horses with penicillin-resistant Bacteroides-infections. The benefits of 
this antimicrobial outweigh the added costs of treatment as it has a high bioavailability and 
only acts on anaerobes. And since it has a high displacement into transcellular spaces such as 
the peritoneal fluid, it makes it an excellent antimicrobial to be used in cases of peritonitis and 
pleuropneumonia. 
It is extremely important to remember in infections with B. fragilis, with the ability for 
abscess formation, that treatment of wounds and abscesses should never solely be attempted 
with antimicrobials. Proper drainage of the abscess and debridement of wounds are the 
cornerstones of good medical practice and cannot be replaced by antimicrobial therapy only. 
Instead antimicrobial therapy should be used in cases where it is absolutely necessary to 
complement the other strategies for the treatment of abscesses and wounds. 
As a final recommendation, as a limited number of isolates were included in this study, it 
would be appropriate to perform future extended studies on Bacteroides spp. from horses to 
further define and establish new treatment regimens for these infections. 
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